|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
| CONTACT-02 Phase III Trial Findings on Cabozantinib-Atezolizumab Combination in mCRPC |
Neeraj Agarwal, MD
Alicia Morgans interviews Neeraj Agarwal about the CONTACT-02 trial, a phase III study that explores the combination of cabozantinib and atezolizumab in patients with metastatic castrate-resistant prostate cancer who have progressed on one novel hormonal therapy. |
|
|
|
|
|
|
|
|
|
|
|
Epidemiology Applied to Focal Therapy in Prostate Cancer: Where do we Stand?
|
Kae Jack Tay, MBBS, MRCS, MMed, MCI, FAMS
Zach Klaassen interviews Jack Tay about the evolution and current practices in focal therapy for prostate cancer. Dr. Tay discusses the precision and reduced toxicity offered by focal therapy, which targets only cancerous tissues within the prostate, sparing non-cancerous areas.
|
|
|
|
|
|
|
|
|
|
|
|
Prognostic Power of Multi-Modal Artificial Intelligence Biomarker in the CHAARTED Trial Subset
|
Mark Markowski, MD, Ph.D.
Zach Klaassen speaks with Mark Markowski about the advancements in AI, particularly the ArteraAI Prostate Test, and its implications for prostate cancer treatment. Dr. Markowski explains how ArteraAI has evolved from predicting treatment responses in localized prostate cancer to potentially guiding treatment decisions in metastatic hormone-sensitive prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer Prognostication
|
Susan Halabi, Ph.D.
Susan Halabi discusses her presentation on prognostic factors in metastatic castration-resistant prostate cancer based on the Alliance trial. This phase three trial, which enrolled 1,311 patients, compared the effects of enzalutamide alone to enzalutamide combined with abiraterone and prednisone.
|
|
|
|
|
|
|
|
|
|
|
|
COBRA Trial: Evaluating 64Cu-SAR-bisPSMA PET Imaging for Prostate Cancer Detection
|
|
Phillip J. Koo, MD
|
| Zachary Klaassen and Phillip Koo discuss the results from the COBRA study, focusing on the innovative 64Cu-SAR-bisPSMA PET imaging. Dr. Koo explains that this new imaging agent has unique dual binding sites and advanced chelator technology, enhancing its attachment to prostate cancer cells and increasing the detection rate.
|
|
|
|
|
|
|
|
|
|
|
|
| PSMA-Targeted Radionuclide Therapy in the Pre- and Post-Chemotherapy Settings in Prostate Cancer |
| Louise Emmett, MD, MBChB, FRACP, FAANMS |
| In a conversation with Phillip Koo, Louise Emmett unpacks the complexities of PSMA-targeted diagnostics and treatments in prostate cancer. They explore the significance of key trials such as ENZA-p, VISION, TheraP, PSMAfore, SPLASH, and ECLIPSE, examining the challenges in proving overall survival benefits and the potential of adaptive dosing strategies for improved patient outcomes. |
|
|
|
|
|
|
|
|
|
|
|
|
Patient Selection for PSMA Radioligand Therapy
|
|
Ephraim Parent, MD, PhD
|
| Phillip Koo engages in a conversation with Ephraim Parent on the pivotal role of PSMA PET imaging in selecting patients for radioligand therapy (RLT). Dr. Parent emphasizes the critical importance of accurately identifying patients through PSMA PET imaging to ensure successful outcomes with Pluvicto therapy.
|
|
|
|
|
|
|
|
|
|
|
|
|
NePtune Trial: Evaluating Neoadjuvant PARP Inhibition in BRCA-Mutated Prostate Cancer
|
|
Rana McKay, MD
|
| Rana McKay discusses the NePtune study, investigating PARP inhibitors as a neoadjuvant treatment for prostate cancer patients with BRCA1/2 mutations.
|
|
|
|
|
|
|
|
|
|
|
|
|
Treating Metastatic Hormone-Sensitive Prostate Cancer: Beyond Counting Metastases
|
|
Karim Fizazi, MD
|
| Alicia Morgans discusses the evolving strategies for treating mHSPC with Karim Fizazi. Professor Fizazi critiques the traditional method of classifying metastatic disease by the volume of metastases, advocating for a more nuanced approach.
|
|
|
|
|
|
|
|
|
|
|
|
|
Darolutamide Outcomes in European Patients with Metastatic Hormone-Sensitive Prostate Cancer from the ARASENS Trial
|
|
Bertrand Tombal, MD, Ph.D.
|
| Alicia Morgans speaks with Bertrand Tombal on the European subset of the ARASENS trial. Professor Tombal discusses the importance of the data from this trial, which assessed the efficacy of adding darolutamide to standard treatment for metastatic hormone-naive prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
|
Comparing PSMA Ligands for Prostate Cancer Imaging
|
|
Michael Hofman, MBBS, FRACP, FAANMS, FICIS, GAICD
|
| Alicia Morgans discusses advances in prostate cancer imaging and theranostics with Michael Hofman. Dr. Hofman emphasizes the growing variety of PSMA ligands for PET-CT imaging and treatment, comparing their subtle differences and implications for clinical practice.
|
|
|
|
|
|
|
|
|
|
|
|
|
Redefining Low-Volume Metastatic Prostate Cancer in the Era of PSMA PET Imaging
|
|
A. Oliver Sartor, MD
|
| Oliver Sartor discusses his approach to treating low-volume metastatic prostate cancer. Dr. Sartor emphasizes the importance of molecular imaging, particularly PSMA PET, to define low-volume and oligometastatic disease accurately.
|
|
|
|
|
|
|
|
|
|
